Filing Details
- Accession Number:
- 0000911916-16-000658
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-09-16 16:45:19
- Reporting Period:
- 2016-09-14
- Filing Date:
- 2016-09-16
- Accepted Time:
- 2016-09-16 16:45:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1348649 | Colucid Pharmaceuticals Inc. | CLCD | Pharmaceutical Preparations (2834) | 203419541 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1639978 | P. Thomas Mathers | C/O Colucid Pharmaceuticals, Inc. 222 Third Street Cambridge MA 02142 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-09-14 | 5,700 | $23.30 | 244,714 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2016-09-14 | 300 | $23.78 | 244,414 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016.
- Represents the sale of 5,700 shares in multiple transactions, ranging in price from $22.73 to $23.72 per share, resulting in a weighted average sale price of $23.3004. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- Represents the sale of 300 shares in multiple transactions, ranging in price from $23.77 to $23.79 per share, resulting in a weighted average sale price of $23.78. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
Billionaire Hedge Funds
